Highlights
-- Completion of dosing in 3rd dose cohort in CHM 1101 (CLTX CAR T) clinical trial
-- Sponsored research agreement with Case Western University to advance Core NK Portfolio
-- Exclusive license agreement with Case Western Reserve University for CORE-NK Platform
For more information, download the attached PDF.
Download this document
